Procter & Gamble to Use Galapagos Adenoviral Tools to Validate Gene Targets | GenomeWeb

NEW YORK, Oct. 22 - Functional genomics company Galapagos Genomics and Procter & Gamble Pharmaceuticals have entered into a gene target-discovery and -validation research collaboration, the firms said on Monday.  

Terms of the two-year agreement call for Galapagos, of Mechelen, Belgium, to supply P&GP with adenoviral vectors that contain human genes selected by P&GP researchers. Galapagos will construct the recombinant adenoviruses using its PhenoSelect expression platform, the company said in a statement. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.